Pharma has only itself to blame for destroying value from its R&D pipeline, according to Andrew Baum, managing director of …

Merck & Co chief executive Kenneth Frazier has expressed concern that European governments increasingly want to pay unrealistically low prices …

John LaMattina joined Pfizer in 1977 after having completed his PhD in organic chemistry, and moved up through the ranks …
Leading pharma firms are getting around 30% less on their investments in research and development compared to last year, according …

